First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens

Journal of Infectious Diseases

Volumn 215, Issue 1, 2017, Pages 95-104

  Nyombayire, Julien ^a   Anzala, Omu ^b   Gazzard, Brian ^c   Karita, Etienne ^a   Bergin, Philip ^d   Hayes, Peter ^d   Kopycinski, Jakub ^d   Omosa Manyonyi, Gloria ^b   Jackson, Akil ^c   Bizimana, Jean ^a   Farah, Bashir ^b   Sayeed, Eddy ^d   Parks, Christopher L ^d   Inoue, Makoto ^f   Hironaka, Takashi ^f   Hara, Hiroto ^f   Shu, Tsugumine ^f   Matano, Tetsuro ^g,h   Dally, Len ^e   Barin, Burc ^e   Park, Harriet ^d   Gilmour, Jill ^d   Lombardo, Angela ^d   Excler, Jean Louis ^d   Fast, Patricia ^d   Laufer, Dagna S ^d   Cox, Josephine H ^d   Ingabire, Rosine ⁱ   Ouattara, Gina ⁱ   Steele, Alan ⁱ   Gumbe, Anne ⁱ   Chinyenze, Kundai ⁱ   Welsh, Sabrina ⁱ   Verlinde, Carl ⁱ   King, Deborah ⁱ   Bishop, Cynthia ⁱ   Chetty, Paramesh ⁱ   Clark, Lorna ⁱ   Booley, Mumtaz ⁱ   Zachariah, Devika ⁱ   Syvertsen, Kristen ⁱ   Anas, Kamaal ⁱ   Naarding, Marloes ⁱ   Cormier, Emmanuel ⁱ   Ackland, Jim ⁱ   Hasegawa, Mamoru ⁱ   more..

^a Projet San Francisco   (Rwanda)

^b Kenya AIDS Vaccine Initiative   (Kenya)

^c CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^e EMMES CORPORATION   (United States)

^f Section of Cell Engineering   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

^h NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

ⁱ NONE

Author keywords

adenovirus 35; HIV 1 vaccine; immunogenicity; intranasal delivery; mucosal responses; prime boost; replication competent; Sendai virus vector

Indexed keywords

ADENOVIRUS 35 VECTORED VACCINE; ADENOVIRUS VACCINE; CONDITIONALLY REPLICATING ADENOVIRUS; HIV TYPE1 GAG VACCINE; INTERLEUKIN 12; INTERLEUKIN 15; UNCLASSIFIED DRUG; VACCINE; VIRUS VECTOR; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; AMINO ACID SEQUENCE; ANTIBODY RESPONSE; BIOCHEMISTRY; BIOPSY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; COLORECTAL BIOPSY; CONFERENCE PAPER; CONTROLLED STUDY; COUGHING; DRUG MEGADOSE; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHEMA; EVALUATION STUDY; FLOW CYTOMETRY; HEMATOLOGY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; INFLUENZA; INJECTION SITE REACTION; LABORATORY TEST; MULTICENTER STUDY; NORMAL HUMAN; NOSE OBSTRUCTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SAFETY; SAMPLE SIZE; SENDAI VIRUS; SINGLE DRUG DOSE; SWELLING; T LYMPHOCYTE; VACCINATION; VIRUS INHIBITION; VIRUS SHEDDING; BLOOD; CELLULAR IMMUNITY; FEMALE; GENE VECTOR; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; KENYA; MALE; MIDDLE AGED; PHYSIOLOGY; RWANDA; SECONDARY IMMUNIZATION; UNITED KINGDOM; VACCINE IMMUNOGENICITY; VIRUS GENE; VIRUS REPLICATION;

ADMINISTRATION, INTRANASAL; ADULT; AIDS VACCINES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENES, VIRAL; GENETIC VECTORS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; IMMUNOGENICITY, VACCINE; KENYA; MALE; MIDDLE AGED; RWANDA; SENDAI VIRUS; UNITED KINGDOM; VACCINES, DNA; VIRUS REPLICATION;

EID: 85027157398     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/INFDIS/JIW500     Document Type: Conference Paper

References (51)

1. Fauci AS, Folkers GK, Marston HD. Ending the global HIV/AIDS pandemic: the critical role of an HIV vaccine. Clin Infect Dis 2014; 59(suppl 2):S80–4.
2. Koff WC, Burton DR, Johnson PR, et al. Accelerating next-generation vaccine development for global disease prevention. Science 2013; 340:1232910.
3. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209–20.
4. Baden LR, Karita E, Mutua G, et al. Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: a randomized trial. Ann Intern Med 2016; 164:313–22.
5. Goepfert PA, Elizaga ML, Seaton K, et al. Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2014; 210:99–110.
6. Kalams SA, Parker SD, Elizaga M, et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 2013; 208:818–29.
7. Mpendo J, Mutua G, Nyombayire J, et al. A phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of electroporated HIV DNA with or without interleukin 12 in prime-boost combinations with an Ad35 HIV vaccine in healthy HIV-seronegative African adults. PLoS One 2015; 10:e0134287.
8. Omosa-Manyonyi G, Mpendo J, Ruzagira E, et al. A phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of an adjuvanted HIV-1 Gag-Pol-Nef fusion protein and adenovirus 35 Gag-RT-Int-Nef vaccine in healthy HIV-uninfected African adults. PLoS One 2015; 10:e0125954.
9. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685–96.
10. Englund JA, Karron RA, Cunningham CK, et al. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children. Vaccine 2013; 31:5706–12.
11. Malkin E, Yogev R, Abughali N, et al. Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age. PLoS One 2013; 8:e77104.
12. Yuki Y, Kiyono H. Mucosal vaccines: novel advances in technology and delivery. Expert Rev Vaccines 2009; 8:1083–97.
13. Wright PF, Mestecky J, McElrath MJ, et al. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J Infect Dis 2004; 189:1221–31.
14. Russell CJ, Hurwitz JL. Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses. Expert Rev Vaccines 2016; 15:189–200.
15. Seki S, Matano T. Development of a Sendai virus vector-based AIDS vaccine inducing T cell responses. Expert Rev Vaccines 2016; 15:119–27.
16. Skiadopoulos MH, Surman SR, Riggs JM, et al. Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees. Virology 2002; 297:153–60.
17. Yonemitsu Y, Kitson C, Ferrari S, et al. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 2000; 18:970–3.
18. Gorman WL, Gill DS, Scroggs RA, Portner A. The hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus type 1 and Sendai virus have high structure-function similarity with limited antigenic cross-reactivity. Virology 1990; 175:211–21.
19. Lyn D, Gill DS, Scroggs RA, Portner A. The nucleoproteins of human parainfluenza virus type 1 and Sendai virus share amino acid sequences and antigenic and structural determinants. J Gen Virol 1991; 72(Pt 4):983–7.
20. Power UF, Ryan KW, Portner A. Sequence characterization and expression of the matrix protein gene of human parainfluenza virus type 1. Virology 1992; 191:947–52.
21. Takimoto T, Bousse T, Portner A. Molecular cloning and expression of human parainfluenza virus type 1 L gene. Virus Res 2000; 70:45–53.
22. Adderson E, Branum K, Sealy RE, et al. Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children. Clin Vaccine Immunol 2015; 22:298–303.
23. Slobod KS, Shenep JL, Lujan-Zilbermann J, et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 2004; 22:3182–6.
24. Hara H, Hara H, Hironaka T, et al. Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors. Hum Vaccin 2011; 7:639–45.
25. Demberg T, Robert-Guroff M. Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol 2009; 28:20–48.
26. Poles J, Alvarez Y, Hioe CE. Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection. AIDS Res Hum Retroviruses 2014; 30:1027–40.
27. Kano M, Matano T, Nakamura H, et al. Elicitation of protective immunity against simian immunodeficiency virus infection by a recombinant Sendai virus expressing the Gag protein. AIDS 2000; 14:1281–2.
28. Matano T, Kano M, Nakamura H, Takeda A, Nagai Y. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen. J Virol 2001; 75:11891–6.
29. Matano T, Kobayashi M, Igarashi H, et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 2004; 199:1709–18.
30. Moriya C, Horiba S, Kurihara K, et al. Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies. Vaccine 2011; 29:8557–63.
31. Keefer MC, Gilmour J, Hayes P, et al. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One 2012; 7:e41936.
32. Stiles T, Grant V, Mawbey T. Good clinical laboratory practice (GCLP). A quality system for laboratories that undertake the analysis of samples from clinical trials. Ipswich, UK: BARQA, 2010.
33. Kato A, Sakai Y, Shioda T, Kondo T, Nakanishi M, Nagai Y. Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells 1996; 1:569–79.
34. Hasan MK, Kato A, Shioda T, Sakai Y, Yu D, Nagai Y. Creation of an infectious recombinant Sendai virus expressing the firefly luciferase gene from the 3′ proximal first locus. J Gen Virol 1997; 78(Pt 11):2813–20.
35. Mutua G, Farah B, Langat R, et al; Hiv-Core 004 Study Group T. Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults. Mol Ther Methods Clin Dev 2016; 3:16061.
36. Bergin PJ, Langat R, Omosa-Manyonyi G, et al. Assessment of anti-HIV-1 antibodies in oral and nasal compartments of volunteers from 3 different populations. J Acquir Immune Defic Syndr 2016; 73:130–7.
37. Omosa-Manyonyi G, Park H, Mutua G, et al. Acceptability and feasibility of repeated mucosal specimen collection in clinical trial participants in Kenya. PLoS One 2014; 9:e110228.
38. Kaltsidis H, Cheeseman H, Kopycinski J, et al. Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trials. J Immunol Methods 2011; 370:43–54.
39. Shacklett BL, Yang O, Hausner MA, et al. Optimization of methods to assess human mucosal T-cell responses to HIV infection. J Immunol Methods 2003; 279:17–31.
40. Spentzou A, Bergin P, Gill D, et al. Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J Infect Dis 2010; 201:720–9.
41. Hayes PJ, Cox JH, Coleman AR, et al. Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition. AIDS 2016; 30:1703–12.
42. Croyle MA, Patel A, Tran KN, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 2008; 3:e3548.
43. De Rosa SC, Thomas EP, Bui J, et al. HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol 2011; 187:3391–401.
44. Lhomme E, Richert L, Moodie Z, et al. Early CD4+ T cell responses are associated with subsequent CD8+ T cell responses to an rAd5-based prophylactic prime-boost HIV vaccine strategy. PLoS One 2016; 11:e0152952.
45. Churchyard GJ, Morgan C, Adams E, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 2011; 6:e21225.
46. Fuchs JD, Bart PA, Frahm N, et al. Safety and immunogenicity of a recombinant adenovirus serotype 35-vectored HIV-1 vaccine in adenovirus serotype 5 seronegative and seropositive individuals. J AIDS Clin Res 2015; 6:461.
47. Graham BS, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006; 194:1650–60.
48. Jaoko W, Karita E, Kayitenkore K, et al. Safety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 2010; 5:e12873.
49. Koup RA, Roederer M, Lamoreaux L, et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010; 5:e9015.
50. Fuchs JD, Frank I, Elizaga ML, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag vaccine (HVTN 090). Open Forum Infect Dis 2015; 2:ofv082.
51. Kalams SA, Parker S, Jin X, et al. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One 2012; 7:e29231.